Sugi Predict

Sugi Predict / Compounds / SCHEMBL1888641

SCHEMBL1888641

SCHEMBL1888641

CC(=O)Nc1ccccc1C(=O)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 4/20 0.65
▸ MAPT P10636 5/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ NPC1 O15118 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ KMT2A Q03164 8/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ POLB P06746 2/20 0.64
▸ HDAC6 Q9UBN7 1/20 0.62
▸ ALDH1A1 P00352 4/20 0.60
▸ HTT P42858 1/20 0.60
▸ RXFP1 Q9HBX9 1/20 0.60
▸ MITF O75030 1/20 0.58
▸ LMNA P02545 3/20 0.57
▸ MAPK1 P28482 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30142774 0.85 SMN1; SMN2 (0.70) ABCG2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL25063089 0.85 SMN1; SMN2 (0.70) ABCG2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6816232 0.84 MAPT (0.70) MAPTSMN1; SMN2KMT2AMEN1POLB
SCHEMBL11783963 0.82 MEN1 (0.68) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL27134473 0.82 KMT2A (0.77) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL24460413 0.82 RORC (0.65) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL28010009 0.81 KMT2A (0.74) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL25063018 0.81 KMT2A (0.66) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL25063077 0.81 CYP1A2 (0.69) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL30142670 0.81 CYP1A2 (0.69) MAPTSMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
CN-116472292-A Modified proteins and protein degrading agents 上海睿跃生物科技有限公司 2023-07-21 — — CN disclosed
EP-4157888-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS Cullgen (Shanghai), Inc. (CN) 2023-04-05 — — EP disclosed
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-02-23 — — US disclosed
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-02-23 — — US disclosed
US-20110256092-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2011-10-20 — — US disclosed
US-7939546-B2 Quinoline derivatives for modulating DNA methylation SUPERGEN, INC. (US) 2011-05-10 — — US disclosed
CN-101889008-A Be used to regulate the quinoline of dna methylation SUPERGEN INC 2010-11-17 — — CN disclosed
US-7790746-B2 Quinoline derivatives for modulating DNA methylation SUPERGEN, INC. (US) 2010-09-07 — — US disclosed
US-20100129320-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2010-05-27 — — US disclosed
EP-2174938-A1 Quinoline derivatives for modulating DNA methylation SuperGen, Inc. (US) 2010-04-14 — — EP disclosed
US-20090285772-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2009-11-19 — — US disclosed
CN-101535295-A Quinoline derivatives for modulating DNA methylation SUPERGEN INC (US) 2009-09-16 — — CN disclosed
US-20090099106-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2009-04-16 — — US disclosed
US-20080175814-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080175814-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L ABCG2 1319/4885MAPT 3156/4885SMN1; SMN2 3304/4885
US-20110256092-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L ABCG2 1319/4885MAPT 3156/4885SMN1; SMN2 3304/4885
US-20090285772-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L ABCG2 1319/4885MAPT 3156/4885SMN1; SMN2 3304/4885
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 ABCG2 2556/4885MAPT 3010/4885SMN1; SMN2 2621/4885
US-20090099106-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L ABCG2 1319/4885MAPT 3156/4885SMN1; SMN2 3304/4885
US-20100129320-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L ABCG2 1319/4885MAPT 3156/4885SMN1; SMN2 3304/4885
US-20230057177-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 ABCG2 2556/4885MAPT 3010/4885SMN1; SMN2 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.